Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA

2016 ◽  
Vol 18 (10) ◽  
pp. 1211-1219 ◽  
Author(s):  
Milton Packer
Keyword(s):  
Heart Failure ◽  
Heart Failure Trial ◽  
The Usa ◽  
Physician Response

Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: Relation with fish intake, circulating biomarkers, and mortality

2013 ◽  
Vol 165 (2) ◽  
pp. 208-215.e4 ◽  
Author(s):  
Serge Masson ◽  
Roberto Marchioli ◽  
Dariush Mozaffarian ◽  
Roberto Bernasconi ◽  
Valentina Milani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Fatty Acids ◽  
Chronic Heart Failure ◽  
Polyunsaturated Fatty Acids ◽  
Fish Intake ◽  
Circulating Biomarkers ◽  
Heart Failure Trial

The African-American heart failure trial (A-HeFT): rationale and methodology*1

2003 ◽  
Vol 9 (5) ◽  
pp. S216-S219 ◽  
Author(s):  
A TAYLOR
Keyword(s):  
Heart Failure ◽  
African American ◽  
American Heart ◽  
Heart Failure Trial

African-American Heart Failure Trial (A-HeFT): Rationale, design, and methodology

2002 ◽  
Vol 8 (3) ◽  
pp. 128-135 ◽  
Author(s):  
Joseph A. Franciosa ◽  
Anne L. Taylor ◽  
Jay N. Cohn ◽  
Clyde W. Yancy ◽  
Susan Ziesche ◽  
...  
Keyword(s):  
Heart Failure ◽  
African American ◽  
American Heart ◽  
Heart Failure Trial

Anaemia and heart failure

Open Medicine ◽  
2011 ◽  
Vol 6 (1) ◽  
pp. 11-25
Author(s):  
Enrico Vizzardi ◽  
Tania Bordonali ◽  
Elena Tanghetti ◽  
Marco Metra ◽  
Livio Cas
Keyword(s):  
Heart Failure ◽  
Ventricular Dysfunction ◽  
Severe Heart Failure ◽  
Left Ventricular ◽  
Favourable Effect ◽  
Heart Failure Trial ◽  
Patients With Heart Failure ◽  
Darbepoetin Alpha ◽  
Main Determinants ◽  
Independent Determinant

AbstractAnaemia is one of the most frequent co-morbidities in patients with heart failure. Its prevalence increases from 4% to7% in subjects with asymptomatic left ventricular dysfunction to >30% in patients with severe heart failure. Renal insufficiency, activation of inflammatory mediators and treatment with renin-angiotensin antagonists seem to be its main determinants. The results of many studies agree in providing evidence that anaemia is a powerful independent determinant of survival in patients with heart failure. However, the mechanisms of this relation are still not fully understood. Moreover a favourable effect of the correction of anaemia on prognosis has not yet been shown. Also In addition to this, controlled studies assessing its effects on exercise tolerance have yielded controversial results. Further research is needed to assess the effect of correcting anaemia in chronic heart failure (CHF) patients; ongoing reduction of events with RED-HF (Darbepoetin alpha in heart failure) trial will help define the role.

Managing heart failure – home or hospital?

1992 ◽  
Vol 30 (16) ◽  
pp. 61-63
Keyword(s):  
Heart Failure ◽  
General Practice ◽  
General Population ◽  
Mortality Rates ◽  
The Usa ◽  
The Uk

In the USA, heart failure affects about 1% of people in their 50s, rising to 10% of those in their 80s,1 and the figure is probably higher in the UK. The symptoms are distressing, usually relentless, and associated with mortality rates four to eight times greater than those in the general population of the same age.1 This article reviews the treatment of uncomplicated heart failure, concentrating on its management in general practice.

Abstract 2140: Infrequent Need for Pacing Following Implantable Cardioverter-Defibrillator Shocks: Analysis of the Sudden Cardiac Death in Heart Failure Trial

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Jordan M Prutkin ◽  
Jeanne E Poole ◽  
George Johnson ◽  
Jill Anderson ◽  
Daniel B Mark ◽  
...  
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Nyha Class ◽  
Prior History ◽  
Baseline Heart Rate ◽  
Implantable Cardioverter Defibrillators ◽  
Heart Failure Trial ◽  
Post Shock

Background: Implantable cardioverter-defibrillators (ICD) are routinely programmed to pace after a shock to prevent possible asystole. In those with no prior history of bradycardia, there is little data regarding the prevalence and characteristics of those who use post-shock pacing (PSP). Methods: We analyzed the occurrence of pacing within the first nine beats after the first successful ICD shock for ventricular tachycardia (VT) or ventricular fibrillation (VF) in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). All ICDs were single lead with the first PSP delivered at 1400msec and all subsequent stimuli delivered at 1200msec. We excluded patients with pacing during pre-shock rhythms and those who had pacing rates different than the protocol default rate of 50bpm (1200 msec). Results: There were 2521 patients enrolled in SCD-HeFT, of which 811 received an ICD. A total of 153 shock events were examined; 36 (23.5%) had at least one of the first nine beats paced post-shock, though only 4 (2.5%) had greater than 4 out of the 9 beats paced. No subjects needed pacing for all nine beats and only 8 (5.2%) paced for greater than 5 seconds. There were no differences in age, gender, etiology of cardiomyopathy, or NYHA class between those with PSP or not. The prevailing heart rate pre-shock was predictive of PSP; the mean cycle length of the baseline rhythm pre-shock was longer (slower rate) for those who used PSP (735 ± 228msec vs. 624 ± 158msec, P=0.001). More often, VF (vs. VT) was the rhythm shocked in those using PSP (P=0.015). A trend also was seen toward increased frequency of PSP in those receiving 30J shocks (16 of 49) versus ≤20J shocks (20 of 104, P=0.068). Conclusion: Patients infrequently require multiple paced beats post-shock for VT or VF. Patients using PSP have a slower baseline heart rate and are more likely to have VF as the shocked rhythm. While 1 or 2 paced beats out of the first nine occurred occasionally, these patients also had rapid return of their native rhythm for which the hemodynamic contribution of 1 or 2 paced beats is unclear. These data suggest that for most patients receiving a primary prevention ICD programmed for shock-only therapy, the need for PSP is limited. PSP use may reflect convention and the assumption that minor post-shock pauses are detrimental.

Sign in / Sign up

Export Citation Format

Share Document